Professor Simon Carding completed postgraduate work at the Medical Research Council’s Clinical Research Centre then undertook postdoctoral work at New York University School of Medicine and Yale University prior to obtaining a faculty position at the University of Pennsylvania, Philadelphia and developing a research programme focusing on gut biology and immunology. Simon returned to the UK and the University of Leeds to develop a new programme of research focusing on commensal gut bacteria (the microbiota) leading to the development of a Bacteroides drug delivery technology platform for new treatments for GI-related diseases.

Simon relocated to the Quadram Institute and the Norwich Medical School at the University East Anglia to develop and lead a multidisciplinary Gut Biology and Microbiology Research Programme. A current research focus is using microbiota-derived products and microvesicles for boosting natural immunity in at risk individuals, and for the delivery of therapeutic proteins and vaccine antigens to mucosal sites to treat or prevent autoimmune- or infection-related diseases that target the GI-tract and other organ systems.

Also of interest is the role of the microbiota in mental health and neurodegenerative diseases (the gut-microbiota-brain axis) which includes the MOTION study, a population based longitudinal study in healthy ageing, investigating the relationship between age-associated changes in the intestinal microbiota and declining cognitive function.